Navigation Links
Medarex Announces 2008 Fourth Quarter and Year End Financial Results
Date:2/25/2009

resented in accordance with GAAP because Medarex's management believes these non-GAAP financial measures provide better insight into Medarex's performance by focusing on results generated by its ongoing operations and are important in comparing current results with prior period results. Non-GAAP net loss and non-GAAP net loss per share are intended to illustrate Medarex's results of operations for the periods presented excluding the items discuss below. Medarex's management believes investors' understanding of Medarex's financial performance is enhanced as a result of our disclosing these non-GAAP financial measures. Non-GAAP net loss and non-GAAP net loss per share should not be viewed in isolation or as a substitute for GAAP net loss or GAAP net loss per share.


                                  MEDAREX, INC.
                 Reconciliation of GAAP Net Loss to Non-GAAP Net Loss
                         (In thousands, except per share data)

                                          Year Ended      Three Months Ended
                                         December 31,        December 31,
                                       -------------------------------------
                                         (unaudited)          (unaudited)
                                        2008      2007       2008     2007
                                        ----      ----       ----     ----
    GAAP Net loss                    $(38,465)  $(27,067) $(42,993) (44,823)
    Celldex Net loss (1)                2,924     15,231         -    3,876
    Minority interest - Celldex (1)         -     (4,699)        -     (157)
    Stock-based compensation
     expense (2)                       22,094     18,551     5,393    4,775
    Acquisition of in-process
     technology                             -      6,900         -        -
    Impairment loss on
     investments in partners            5,298      2,141     5,298        -
 
'/>"/>
SOURCE Medarex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody
2. Medarex to Present at the JPMorgan Small/Mid Cap Conference
3. PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM)
4. Medarex to Receive Milestone Payment for Submission of Regulatory Applications Requesting Approval of Ustekinumab (CNTO 1275) for Treatment of Psoriasis
5. Medarex to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
6. Medarex Announces 2007 Fourth Quarter and Year End Financial Results
7. Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab
8. Medarex Announces 2008 First Quarter Financial Results
9. Medarex Hosts June 2nd Webcast of Ipilimumab Data Presented at ASCO
10. Medarex to Receive Milestone Payment for Approval of STELARA(TM) (Ustekinumab) for the Treatment of Moderate to Severe Plaque Psoriasis
11. Medarex Reviews Recent Highlights and Outlook for 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... -- In people with sex addiction, pornography affects the ... in drug addicts as they consume drugs, a new ... activity between patients who have compulsive sexual behavior and ... study author Dr. Valerie Voon, of the University of ... Voon,s research involved 19 men with sex addiction ...
(Date:7/11/2014)... (HealthDay News) -- U.S. health officials have concluded that ... live anthrax during a safety mishap last month. ... officials have announced a moratorium on the transfer of ... In a report issued Friday, the CDC outlined ... a similar incident doesn,t occur again. Last month, as ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 The ... Supplements, Specialty Nutrients, Animal Feed), Applications (Regular, Therapeutic, ... - Global Trends & Forecasts to 2019 ” ... an analysis and forecasting of the market value ... identifies the driving and restraining factors for the ...
(Date:7/11/2014)... to a new market research report “Internet of Things ... Bluetooth, Wi-Fi, NFC, RFID), Application Vertical (Building Automation, Consumer, ... - Global Trends & Forecasts to 2014 - 2020”, ... $1029.5 Billion in 2013, and is expected to reach ... 4.08% from 2014 to 2020. , Browse more ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Biostimulants are ... growth in turf and ornamentals. These also help turf ... improve length of roots. Turf, ornamentals, and flowers appear ... Therefore, this usage has increased from the last few ... turf and ornamentals is Europe, with around 40% share ...
Breaking Medicine News(10 mins):Health News:Brains of Sex Addicts May Be Wired Like Those of Drug Addicts, Study Finds 2Health News:CDC Issues Tough Report on Anthrax Scare 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 3Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 4Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 5Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 3
... of blood tests over skin tests for detecting people ... effective, reliable and therefore holds promise in detecting latent ... dormant TB infection never actually get a full blown ... cases and offer treatment, which would take the pursuit ...
... a breach of trust if the court orders to release a ... and a patient.// The hospital said that it would do everything ... had an abortion at 32 weeks' pregnancy. She plans to take ... Appeal ordered that the woman's files be released to the Medical ...
... more number of bus drivers and conductors in India are ... of the bus conductor Ravindra Kamble (34). //Statistics show that ... year have been tested positive for HIV. The BEST’s HIV ... the previous year. ,He took the initiative for ...
... stem cell products through an IV line, in the years ... heart muscle in patients who have experienced heart attack for ... distinct advantage of the procedure is that intravenous infusion of ... a healthy donor can reverse heart tissue damage, elimininating the ...
... about increased risk of birth defects associated with letrozole, ... commonly given for infertility treatment has been settled//. A ... birth defects associated with letrozole is very similar to ... for infertility for more than 40 years that is ...
... that are associated with the menopause and dry eye is ... that the symptom is associated with the menopause or peri-menopause. ... risk of infection or visual impairment. ,The survey, sponsored ... percent of menopausal and peri-menopausal women reported that they experience ...
Cached Medicine News:Health News:Bad Publicity for the Hospital With Respect To Dwarfism Abortion Case 2Health News:Stem Cell Therapy Regenerates Heart Muscle In Heart Attack Patients 2Health News:Dry Eye Is A Symptom Of Menopause 2
(Date:7/10/2014)... July 10, 2014 Integrated Silicon Solution, Inc. ... memory and analog IC solutions, today announced that it ... 24, 2014, at 7:00 a.m. Pacific Time (10:00 a.m. ... the fiscal 2014 third quarter ended June 30, 2014. ... dial 1-888-556-4997 before 6:50 a.m. Pacific time on July ...
(Date:7/10/2014)... 10, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... has completed the sale to Galderma of all rights ... held by Valeant for $1.4 billion in cash, pursuant ... recently completed its acquisition of Galderma. ... products to a company that is firmly committed to ...
(Date:7/10/2014)... -- CVS Caremark Corporation (NYSE: CVS ) today ... dividend of $0.275 (27.5 cents) per share on the corporation,s ... to holders of record on July 21, 2014. ... to helping people on their path to better health as ... States . Through the company,s more than 7,600 CVS/pharmacy ...
Breaking Medicine Technology:
The BioPro Basal Thumb joint is manufactured from Cobalt Chrome and is used to replace the Trapeziometacarpal joint....
... Fusion Screw is a headless ... of variable thread pitch and ... holding power. The Acutrak Fusion ... of the IP and DIP ...
The efficient choice for small joint replacement technology -- the Ascension Silicone MCP features a similar design to our PyroCarbon MCP and utilizes the same instrumentation for intra-operative fle...
A flexible intramedullary-stemmed, one-piece implant developed as an adjunct to resection arthroplasty to help restore function to hands disabled by rheumatoid, degenerative or post-traumatic arthrit...
Medicine Products: